Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Veloxis Pharmaceuticals.

    Client Virtual Booth

    VELOXIS PHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Veloxis Pharmaceuticals
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1001 Winstead Drive, Cary, NC 27513
    Telephone
    Telephone
    1 919 591 3090
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.panpharma.eu/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/panpharma/?originalSubdomain=fr
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard® in Patients with Stero...

    Details:

    T-Guard (ricin toxin A conjugated mAB) is designed to reset the body's immune system in life-threatening T cell‒mediated conditions, potentially including prevention of transplant-related rejection, treatment of acute solid-organ rejection, and severe autoimmune disease.


    Lead Product(s): Ricin Toxin A Conjugated Monoclonal Antibodies

    Therapeutic Area: Immunology Product Name: T-Guard

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Xenikos B.V

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 28, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant...

    Details:

    VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.


    Lead Product(s): FR104

    Therapeutic Area: Immunology Product Name: VEL-101

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: OSE Immunotherapeutics SA

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 18, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Investigational Drug for Kidney Transplant Immu...

    Details:

    VEL-101 (FR104) is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.


    Lead Product(s): VEL-101

    Therapeutic Area: Immunology Product Name: FR104

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Asahi Kasei Pharma

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 18, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104

    Details:

    The collaboration grants Veloxis worldwide rights to develop, manufacture and commercialize FR104, a CD28 antagonist monoclonal antibody fragment, for all transplant indications. OSE Immunotherapeutics retains all rights to develop FR104 in autoimmune diseases.


    Lead Product(s): FR104

    Therapeutic Area: Immunology Product Name: FR104

    Highest Development Status: Phase IProduct Type: Large molecule

    Recipient: OSE Immunotherapeutics SA

    Deal Size: $393.6 million Upfront Cash: $8.5 million

    Deal Type: Collaboration April 26, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search